TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+13.64%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.46B
AUM Growth
+$2.46B
(+5.4%)
Cap. Flow
-$90.4M
Cap. Flow
% of AUM
-3.67%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
213
New
10
Increased
47
Reduced
70
Closed
17
Top Buys
| 1 |
Pfizer
PFE
|
$23.5M |
| 2 |
Merck
MRK
|
$21.2M |
| 3 |
Welltower
WELL
|
$14.9M |
| 4 |
Eli Lilly
LLY
|
$10.2M |
| 5 |
CELG
Celgene Corp
CELG
|
$8.65M |
Top Sells
| 1 |
Biogen
BIIB
|
$19.1M |
| 2 |
Johnson & Johnson
JNJ
|
$18.8M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$16.3M |
| 4 |
AbbVie
ABBV
|
$13.9M |
| 5 |
Thermo Fisher Scientific
TMO
|
$13.5M |
Sector Composition
| 1 | Healthcare | 94.43% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $139M | 5.65% | 1,473,710 +91,704 | +7% | +$8.65M |
|
2
Amgen
AMGN
$155B
| $134M | 5.43% | 704,383 +26,528 | +4% | +$5.04M |
|
|
3
Johnson & Johnson
JNJ
$427B
| $126M | 5.1% | 897,990 -134,638 | -13% | -$18.8M |
|
4
Gilead Sciences
GILD
$140B
| $114M | 4.62% | 1,749,388 -140,458 | -7% | -$9.13M |
|
|
5
Pfizer
PFE
$141B
| $87.9M | 3.57% | 2,070,765 +553,972 | +37% | +$23.5M |
|
|
6
Merck
MRK
$210B
| $82.6M | 3.35% | 993,083 +254,975 | +35% | +$21.2M |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $81.6M | 3.31% | 443,712 +17,464 | +4% | +$3.21M |
|
8
UnitedHealth
UNH
$281B
| $80.1M | 3.25% | 324,133 -51,241 | -14% | -$12.7M |
|
|
9
Biogen
BIIB
$19.4B
| $74.3M | 3.02% | 314,278 -80,624 | -20% | -$19.1M |
|
10
Illumina
ILMN
$15.8B
| $73.8M | 3% | 237,514 -24,865 | -9% | -$7.73M |
|
11
Regeneron Pharmaceuticals
REGN
$61.5B
| $58.1M | 2.36% | 141,532 +5,110 | +4% | +$2.1M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $50.8M | 2.06% | 375,705 -120,583 | -24% | -$16.3M |
|
13
Incyte
INCY
$16.5B
| $45.5M | 1.85% | 529,133 -116,309 | -18% | -$10M |
|
14
Medtronic
MDT
$119B
| $44.8M | 1.82% | 492,002 +10,637 | +2% | +$969K |
|
15
Elevance Health
ELV
$71.8B
| $40.6M | 1.65% | 141,358 +211 | +0.1% | +$60.6K |
|
|
16
Thermo Fisher Scientific
TMO
$186B
| $39.1M | 1.59% | 142,743 -49,152 | -26% | -$13.5M |
|
|
17
Eli Lilly
LLY
$657B
| $38.3M | 1.56% | 295,320 +78,878 | +36% | +$10.2M |
|
18
Abbott
ABT
$231B
| $36.5M | 1.48% | 457,048 +65,329 | +17% | +$5.22M |
|
19
Bristol-Myers Squibb
BMY
$96B
| $35.2M | 1.43% | 738,044 +85,078 | +13% | +$4.06M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $28.3M | 1.15% | 193,263 -41,457 | -18% | -$6.07M |
|
21
CVS Health
CVS
$92.8B
| $27.3M | 1.11% | 506,364 +45,666 | +10% | +$2.46M |
|
22
Viatris
VTRS
$12.3B
| $26.7M | 1.09% | 943,152 -460,576 | -33% | -$13.1M |
|
23
Novartis
NVS
$245B
| $26.6M | 1.08% | 276,847 -14,870 | -5% | -$1.43M |
|
24
Zoetis
ZTS
$69.3B
| $25.9M | 1.05% | 257,001 +5,586 | +2% | +$562K |
|
|
25
AbbVie
ABBV
$372B
| $25.8M | 1.05% | 320,213 -171,865 | -35% | -$13.9M |
|